ERT following IORT improves survival of patients with resectable pancreatic cancer

被引:0
|
作者
Yamaguchi, K [1 ]
Nakamura, K
Kobayashi, K
Nakano, K
Konomi, H
Mizumoto, K
Tanaka, M
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 8128582, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Radiat Therapy, Fukuoka 8128582, Japan
关键词
intraoperative radiation therapy; external radiation therapy; pancreatic head cancer;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The clinical course of patients with pancreatic carcinoma remains dismal despite the recent advances of diagnostic and therapeutic procedures. One of the main causes is residual carcinoma cells, especially at the retroperitoneal aspect after pancreatectomy. Radiation therapy (RT) [intraoperative radiation therapy (IORT) and external radiation therapy (ERT)] is a therapeutic strategy to conquer the remaining cancer cells. Methodology: Effects of RT were retrospectively examined in 81 patients with pancreatectomy for pancreatic cancer together with early and late complications. Results: Preoperative clinical data were not different between the RT(+) and RT(-) groups excluding peripheral lymphocyte counts. Postoperative early complications equally occurred including pancreatic fistula. Regarding late complications (> 2 months after operation), stomal ulcer, vertebral fracture, pseudoaneurysm, intraabdominal hemorrhage, and liver abscess were present only in patients with RT. Glucose intolerance tended to be more frequent in the RT (+) group, i.e. 12 (63%) of the 19 with RT examined and 14 (42%) of the 33 without RT examined. Follow-up imaging showed recurrence in 27 (71%) of the 38 patients without RT and 13 (52%) of the 25 patients with RT. The sites of the recurrence were not different by the presence or absence of RT. One-year, 3-year and 5-year cumulative survival rates were similar between the RT (-) group (100%, 39%, 21%, respectively) and IORT (+) alone group (100%, 29% and 17%, respectively). The rates in the IORT (+) and ERT W group were 100%, 54% and 28%, respectively, which tended to be better than those in the other two groups, but the differences were not statistically significant. Conclusions: These findings suggest that only the combination of IORT and ERT somewhat improves the short-term clinical course of patients with resectable pancreatic cancer, although there are some RT-related late complications. It is recommended that ERT be added to IORT after pancreatectomy for pancreatic cancer to improve the clinical course, once IORT has been performed.
引用
收藏
页码:1244 / 1249
页数:6
相关论文
共 50 条
  • [1] Will IORT improve survival rates in patients with pancreatic cancer?
    Matamoros, A
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (03): : 303 - 304
  • [2] Borderline Resectable Pancreatic Cancer Patients Have Superior Survival Following Neoadjuvant Therapy Compared to Upfront Resectable Patients
    Deig, C.
    Trone, K.
    Beneville, B.
    Stratton, A.
    Liu, A.
    Kanwar, A.
    Grossblatt-Wait, A.
    Sheppard, B.
    Attia, F.
    Bassale, S.
    Chen, Y.
    Keith, D.
    Chen, E.
    Lopez, C.
    Gilbert, E.
    Billingsley, K.
    Nabavizadeh, N.
    Thomas, C. R., Jr.
    Grossberg, A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E581 - E582
  • [3] Multi-agent neoadjuvant chemotherapy improves response and survival in patients with resectable pancreatic cancer
    Blinn, Paige
    Shridhar, Ravi
    Maramara, Taylor
    Huston, Jamie
    Meredith, Kenneth
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 11 (05) : 1078 - 1089
  • [4] Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement
    Akahori, Takahiro
    Terai, Taichi
    Nagai, Minako
    Nakamura, Kota
    Kohara, Yuichiro
    Yasuda, Satoshi
    Matsuo, Yasuko
    Doi, Shunsuke
    Sakata, Takeshi
    Sho, Masayuki
    [J]. ANNALS OF GASTROENTEROLOGICAL SURGERY, 2024, 8 (01): : 151 - 162
  • [5] Survival of resectable pancreatic cancer patients with diabetes.
    Busaidy, N. L.
    Yazbeck, C. F.
    Shah, P.
    Evans, D. B.
    Li, D.
    Geraci, J. M.
    Weiser, M. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 202S - 202S
  • [6] Multi-agent neoadjuvant chemotherapy improves response and survival in patients with resectable pancreatic cancer.
    Maramara, Taylor
    Huston, Jamie
    Shridhar, Ravi
    Meredith, Kenneth L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer
    Plvi Vento
    Harri Mustonen
    Timo Joensuu
    Pivi Krkkinen
    Eero Kivilaakso
    Tuula Kiviluoto
    [J]. World Journal of Gastroenterology, 2007, (21) : 2945 - 2951
  • [8] Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer
    Vento, Palvi
    Mustonen, Harri
    Joensuu, Timo
    Kaerkkaeinen, Paivi
    Kivilaakso, Eero
    Kiviluoto, Tuula
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (21) : 2945 - 2951
  • [9] Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma
    Chen, Ru
    Dawson, David W.
    Pan, Sheng
    Ottenhof, Niki A.
    De Wilde, Roeland F.
    Wolfgang, Christopher L.
    May, Damon H.
    Crispin, David A.
    Lai, Lisa A.
    Lay, Anna R.
    Waghray, Meghna
    Wang, Shouli
    McIntosh, Martin W.
    Simeone, Diane M.
    Maitra, Anirban
    Brentnall, Teresa A.
    [J]. LABORATORY INVESTIGATION, 2015, 95 (01) : 43 - 55
  • [10] Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma
    Chen, Ru
    Pan, Sheng
    Maitra, Anirban
    Simeone, Diane
    Dawson, David
    Brentnall, Teresa
    [J]. CANCER RESEARCH, 2014, 74 (19)